يعرض 1 - 10 نتائج من 38 نتيجة بحث عن '"Jin, Qingchun"', وقت الاستعلام: 1.33s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
  10. 10
    دورية أكاديمية

    مصطلحات موضوعية: Internal Medicine and Specialties, Health Sciences

    وصف الملف: application/pdf

    العلاقة: Singal, Amit G.; Tayob, Nabihah; Mehta, Anand; Marrero, Jorge A.; El-Serag, Hashem; Jin, Qingchun; Saenz de Viteri, Cristian; Fobar, Austin; Parikh, Neehar D. (2022). "GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis." Hepatology (3): 541-549.; https://hdl.handle.net/2027.42/171814Test; Hepatology; Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, et al. Role of the GALAD and BALAD- 2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016; 14 ( 6 ): 875 - 86.e6.; Singal AG, Tiro JA, Murphy CC, Blackwell J- M, Kramer JR, Khan A, et al. Patient- reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multi- center cohort of patients with cirrhosis. Clin Gastroenterol Hepatol. 2021; 19 ( 5 ): 987 - 95.e1.; Parikh ND, Mehta A, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2020; 29 ( 12 ): 2495 - 503.; Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault J- C, Paradis V, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021; 160 ( 7 ): 2572 - 84.; Tayob N, Lok AS, Do KA, Feng Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha- fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016; 14 ( 3 ): 469 - 75.e2.; Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012; 21 ( 5 ): 793 - 9.; Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, et al. Clinical utility of highly sensitive Lens culinaris agglutin- reactive alpha- fetoprotein in hepatocellular carcinoma patients with alpha fetoprotein; El- Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory- based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014; 146 ( 5 ): 1249 - 55.e1.; Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, et al. Validation of the updated hepatocellular carcinoma early detection screening algorithm in a community- based cohort of patients with cirrhosis of multiple etiologies. Clin Gastroenterol Hepatol. 2021; 19 ( 7 ): 1443 - 50.; Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014; 23 ( 1 ): 144 - 53.; McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003; 4 ( 1 ): 27 - 40.; Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis. Hepatology. 2020; 72 ( 5 ): 1654 - 65.; Losic B, Craig AJ, Villacorta- Martin C, Martins- Filho SN, Akers N, Chen X, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun. 2020; 11: 291.; Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2019; 28 ( 3 ): 531 - 8.; Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93: 1054 - 61.; Best J, Bechmann LP, Sowa J- P, Sydor S, Dechêne A, Pflanz K, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020; 18 ( 3 ): 728 - 35.; Tayob N, Lok AS, Do K, Feng Z. Improved detection of hepatocellular carcinoma using a longitudinal alpha- fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016; 14 ( 3 ): 469 - 75.; Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020; 72 ( 2 ): 250 - 61.; Singal AG, Nehra M, Adams- Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT- C trial: where did surveillance fail? Am J Gastroenterol. 2013; 108 ( 3 ): 425 - 32.; Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta- analysis. Hepatology. 2021; 73 ( 2 ): 713 - 25.; Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019; 17 ( 4 ): 766 - 73.; Woolen SA, Singal AG, Davenport MS, Troost JP, Khalatbari S, Mittal S, et al. Patient preferences for hepatocellular carcinoma surveillance parameters: a multicenter conjoint study. Clin Gastroenterol. 2021. https://doi.org/10.1016/j.cgh.2021.02.024Test; Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, et al. Design of the Texas Hepatocellular Carcinoma Consortium Cohort study. Am J Gastroenterol. 2019; 114 ( 3 ): 530 - 2.; Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, et al. Rationale and design of the hepatocellular carcinoma early detection strategy study: a multi- center longitudinal initiative of the National Cancer Institute- s Early Detection Research Network. Contemp Clin Trials. 2019; 76: 49 - 54.; Marrero JA, Feng Z, Wang Y, Nguyen M, Befeler AS, Roberts LR, et al. Alpha- fetoprotein, des- gamma carboxprothrombin, and lectin- bound alpha- fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137 ( 1 ): 110 - 8.; Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020; 18 ( 12 ): 2650 - 66.; Llovet J, Fuster J, Bruix J. Intention- to- treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30 ( 6 ): 1434 - 40.; Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020; 51 ( 1 ): 78 - 89.; Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68 ( 2 ): 723 - 50.; Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J- L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69 ( 1 ): 182 - 236.; Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta- analysis. Gastroenterology. 2018; 154 ( 6 ): 1706 - 18.; Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017; 45 ( 1 ): 169 - 77.; Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014; 12 ( 11 ): 1927 - 933.; Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017; 65 ( 4 ): 1196 - 205.; Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, et al. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. Clin Gastroenterol Hepatol. 2021; 19 ( 9 ): 1925 - 32.; Farvardin S, Patel J, Khambaty M, Yerokun O, Mok H, Tiro JA, et al. Patient- reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017; 65 ( 3 ): 875 - 84.